Immunogenicity after the First Dose of the BNT162b2 mRNA COVID-19 Vaccine: Real-World Evidence from Greek Healthcare Workers by Konstantina Kontopoulou, Alexandra Ainatzoglou, Athina Ifantidou, Christos Nakas, Georgia Goudi, Eleni Antoniadou, Vasilios Adamopoulos, Nikitas Papadopoulos, Georgios Papazisis :: SSRN

Immunogenicity after the First Dose of the BNT162b2 mRNA COVID-19 Vaccine: Real-World Evidence from Greek Healthcare Workers by Konstantina Kontopoulou, Alexandra Ainatzoglou, Athina Ifantidou, Christos Nakas, Georgia Goudi, Eleni Antoniadou, Vasilios Adamopoulos, Nikitas Papadopoulos, Georgios Papazisis :: SSRN: Background: The BNT162b2 mRNA Covid-19 vaccine that was recently launched exhibited high levels of efficacy and safety in a phase III RCT, along with robust imm